## CLAIMS

- 1. Use of rhein and rhein derivatives in human or veterinary therapeutics for the treatment of an affection requiring an increase of the levels of the heme oxygenase enzyme.
- 2. Use according to claim 1, wherein rhein and the rhein derivative are represented by the following general formula (I):

15

30

in which R represents a hydrogen atom, or an alkyl group, or an alkaline or hearth-alkaline metal atom,  $R_1$  and  $R_2$ , identical or different, represent a hydroxy group or an acyloxy group of formula R'-COO- where R' is an alkyl group of 1 to 4 carbon atoms.

- 3. Use according to claim 2, wherein the derivative is rhein or diacerein.
  - 4. Use according to any of the preceding claims, wherein the rhein derivative is administered at a dose of 25 to 500 mg per day.
- 5. Use according to any of the preceding claims, wherein the rhein derivative is under a form which can be administered per oral route.
  - 6. Use of rhein and rhein derivatives for the manufacture of a medicinal product for the treatment of an affection requiring an increase of the levels of the heme oxygenase enzyme.
  - 7. Use according to claim 6, wherein rhein and the rhein derivative are represented by the following general formula (I):

5

30

- in which R represents a hydrogen atom, or an alkyl group, or an alkaline or hearth-alkaline metal atom,  $R_1$  and  $R_2$ , identical or different, represent a hydroxy group or an acyloxy group of formula R'-COO- where R' is an alkyl group of 1 to 4 carbon atoms.
- 8. Use according to claim 7, wherein the derivative is rhein or diacerein.
  - 9. Use according to any of claims 6 to 8, wherein the rhein derivative is administered at a dose of 25 to 500 mg per day.
- 10. Use according to any of claims 6 to 9, wherein the rhein derivative is under a form which can be administered per oral route.
  - 11. Use according to claim 10, wherein the unitary dose is comprised between  $25\ \mathrm{mg}$  and  $50\ \mathrm{mg}$ .
- 12. Use according to any of claims 6 to 11, wherein the rhein derivative is associated with a non-steroidal anti-inflammatory drug (NSAID) or with a COX-2 inhibitor.
  - 13. Use according to any of claims 6 to 12, wherein the treatment is intended to cure or prevent transplant rejections.
  - 14. Use according to any of claims 6 to 12, wherein the treatment is intended to prevent and inhibit the effects of stress on cells and tissues.